Biblio

Export 1455 results:
Author [ Title(Desc)] Type Year
Filters: First Letter Of Last Name is K  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
S. Akoudad, M Gurol, E., Fotiadis, P., Koudstaal, P. J., Hofman, A., M Ikram, A., Greenberg, S. M., and Vernooij, M. W., “Cerebral Microbleeds and Cerebrovascular Reactivity in the General Population: The EDAN Study.”, J Alzheimers Dis, vol. 53, no. 2, pp. 497-503, 2016.
Y. Hatada, Hashimoto, M., Shiraishi, S., Ishikawa, T., Fukuhara, R., Yuki, S., Tanaka, H., Miyagawa, Y., Kitajima, M., Uetani, H., Tsunoda, N., Koyama, A., and Ikeda, M., “Cerebral Microbleeds Are Associated with Cerebral Hypoperfusion in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 71, no. 1, pp. 273-280, 2019.
Y. Hatada, Hashimoto, M., Shiraishi, S., Ishikawa, T., Fukuhara, R., Yuki, S., Tanaka, H., Miyagawa, Y., Kitajima, M., Uetani, H., Tsunoda, N., Koyama, A., and Ikeda, M., “Cerebral Microbleeds Are Associated with Cerebral Hypoperfusion in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 71, no. 1, pp. 273-280, 2019.
F. Rokad, Moseley, R., Hardy, R. S., Chukkapalli, S., Crean, S. J., Kesavalu, L., and Singhrao, S. K., “Cerebral Oxidative Stress and Microvasculature Defects in TNF-α Expressing Transgenic and Porphyromonas gingivalis-Infected ApoE-/- Mice.”, J Alzheimers Dis, vol. 60, no. 2, pp. 359-369, 2017.
N. Wang, Allali, G., Kesavadas, C., Noone, M. L., Pradeep, V. G., Blumen, H. M., and Verghese, J., “Cerebral Small Vessel Disease and Motoric Cognitive Risk Syndrome: Results from the Kerala-Einstein Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 699-707, 2016.
B. - L. Ho, Kao, Y. - H., Chou, M. - C., and Yang, Y. - H., “Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 1, pp. 351-7, 2016.
J. J. Claus, Coenen, M., Staekenborg, S. S., Schuur, J., Tielkes, C. E. M., Koster, P., and Scheltens, P., “Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population.”, J Alzheimers Dis, 2018.
I. van Steenoven, Aarsland, D., Weintraub, D., Londos, E., Blanc, F., van der Flier, W. M., Teunissen, C. E., Mollenhauer, B., Fladby, T., Kramberger, M. G., Bonanni, L., and Lemstra, A. W., “Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.”, J Alzheimers Dis, vol. 54, no. 1, pp. 287-95, 2016.
K. Kawamura, Miyajima, M., Nakajima, M., Kanai, M., Motoi, Y., Nojiri, S., Akiba, C., Ogino, I., Xu, H., Kamohara, C., Yamada, S., Karagiozov, K., Ikeuchi, T., Kondo, A., and Arai, H., “Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 83, no. 1, pp. 179-190, 2021.
K. Kawamura, Miyajima, M., Nakajima, M., Kanai, M., Motoi, Y., Nojiri, S., Akiba, C., Ogino, I., Xu, H., Kamohara, C., Yamada, S., Karagiozov, K., Ikeuchi, T., Kondo, A., and Arai, H., “Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 83, no. 1, pp. 179-190, 2021.
K. Kawamura, Miyajima, M., Nakajima, M., Kanai, M., Motoi, Y., Nojiri, S., Akiba, C., Ogino, I., Xu, H., Kamohara, C., Yamada, S., Karagiozov, K., Ikeuchi, T., Kondo, A., and Arai, H., “Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 83, no. 1, pp. 179-190, 2021.
K. Kawamura, Miyajima, M., Nakajima, M., Kanai, M., Motoi, Y., Nojiri, S., Akiba, C., Ogino, I., Xu, H., Kamohara, C., Yamada, S., Karagiozov, K., Ikeuchi, T., Kondo, A., and Arai, H., “Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 83, no. 1, pp. 179-190, 2021.
K. Kawamura, Miyajima, M., Nakajima, M., Kanai, M., Motoi, Y., Nojiri, S., Akiba, C., Ogino, I., Xu, H., Kamohara, C., Yamada, S., Karagiozov, K., Ikeuchi, T., Kondo, A., and Arai, H., “Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 83, no. 1, pp. 179-190, 2021.
B. M. Bettcher, Johnson, S. C., Fitch, R., Casaletto, K. B., Heffernan, K. S., Asthana, S., Zetterberg, H., Blennow, K., Carlsson, C. M., Neuhaus, J., Bendlin, B. B., and Kramer, J. H., “Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage.”, J Alzheimers Dis, vol. 62, no. 1, pp. 385-397, 2018.
P. Lewczuk, Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. Luis, Eusebi, P., Kornhuber, J., Morris, J. C., and Fagan, A. M., “Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 813-822, 2017.
C. Gervaise-Henry, Watfa, G., Albuisson, E., Kolodziej, A., Dousset, B., Olivier, J. - L., Jonveaux, T. Rivasseau, and Malaplate-Armand, C., “Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.”, J Alzheimers Dis, vol. 57, no. 2, pp. 437-445, 2017.
S. Wolfsgruber, Polcher, A., Koppara, A., Kleineidam, L., Frölich, L., Peters, O., Hüll, M., Rüther, E., Wiltfang, J., Maier, W., Kornhuber, J., Lewczuk, P., Jessen, F., and Wagner, M., “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
S. Wolfsgruber, Polcher, A., Koppara, A., Kleineidam, L., Frölich, L., Peters, O., Hüll, M., Rüther, E., Wiltfang, J., Maier, W., Kornhuber, J., Lewczuk, P., Jessen, F., and Wagner, M., “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
S. Wolfsgruber, Polcher, A., Koppara, A., Kleineidam, L., Frölich, L., Peters, O., Hüll, M., Rüther, E., Wiltfang, J., Maier, W., Kornhuber, J., Lewczuk, P., Jessen, F., and Wagner, M., “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
G. P. Paraskevas, Kasselimis, D., Kourtidou, E., Constantinides, V., Bougea, A., Potagas, C., Evdokimidis, I., and Kapaki, E., “Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1453-1461, 2017.
G. P. Paraskevas, Kasselimis, D., Kourtidou, E., Constantinides, V., Bougea, A., Potagas, C., Evdokimidis, I., and Kapaki, E., “Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1453-1461, 2017.
G. P. Paraskevas, Kasselimis, D., Kourtidou, E., Constantinides, V., Bougea, A., Potagas, C., Evdokimidis, I., and Kapaki, E., “Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1453-1461, 2017.
S. P. Arnerić, Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. Forrest, Hitchcock, J., Kaplow, J., Luthman, J., Meibach, R., Raunig, D., Romero, K., Samtani, M. N., Savage, M., Shaw, L., Stephenson, D., Umek, R. M., Vanderstichele, H., Willis, B., and Yule, S., “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
A. Kimura, Yoshikura, N., Hayashi, Y., and Inuzuka, T., “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.

Pages